PRESS RELEASE published on 08/21/2023 at 12:45, 2 years 3 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE published on 07/11/2023 at 12:45, 2 years 4 months ago Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE published on 07/06/2023 at 12:45, 2 years 4 months ago Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
PRESS RELEASE published on 06/29/2023 at 12:45, 2 years 5 months ago NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
PRESS RELEASE published on 05/31/2023 at 12:40, 2 years 6 months ago NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
PRESS RELEASE published on 05/16/2023 at 12:45, 2 years 6 months ago NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
PRESS RELEASE published on 04/25/2023 at 12:45, 2 years 7 months ago NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
PRESS RELEASE published on 04/17/2023 at 12:45, 2 years 7 months ago NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
PRESS RELEASE published on 04/04/2023 at 13:45, 2 years 8 months ago NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
PRESS RELEASE published on 02/15/2023 at 12:30, 2 years 9 months ago NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials
Published on 12/05/2025 at 02:35, 8 hours 14 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 9 hours 49 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 11 hours 44 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 11 hours 49 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 10:30, 19 minutes ago Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 34 minutes ago Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 1 hour 9 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 1 hour 19 minutes ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 1 hour 44 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 08:45, 2 hours 4 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 2 hours 4 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 2 hours 7 minutes ago ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 16 hours 34 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 16 hours 49 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
